How are BEAM straddle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the BEAM straddle priced from the end-of-day chain at a 30-day expiry (ATM IV 77.60%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$472.47 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a BEAM straddle?

The breakeven for the BEAM straddle priced on this page is roughly $30.23 and $39.78 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current BEAM market-implied 1-standard-deviation expected move is approximately 22.25%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current BEAM implied volatility affect this straddle?

BEAM ATM IV is at 77.60% with IV rank near 37.58%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.

BEAM Straddle Strategy

BEAM (Beam Therapeutics Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia.

BEAM (Beam Therapeutics Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $3.58B, a beta of 2.20 versus the broader market, a 52-week range of 15.6-36.88, average daily share volume of 2.1M, a public-listing history dating back to 2020, approximately 393 full-time employees. These structural characteristics shape how BEAM stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 2.20 indicates BEAM has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a straddle on BEAM?

A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration.

Current BEAM snapshot

As of June 29, 2026, spot at $34.77, ATM IV 77.60%, IV rank 37.58%, expected move 22.25%. The straddle on BEAM below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 18-day expiry.

Why this straddle structure on BEAM specifically: BEAM IV at 77.60% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 22.25% (roughly $7.74 on the underlying). The 18-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated BEAM expiries trade a higher absolute premium for lower per-day decay. Position sizing on BEAM should anchor to the underlying notional of $34.77 per share and to the trader's directional view on BEAM stock.

BEAM straddle setup

The BEAM straddle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With BEAM near $34.77, the first option leg uses a $35.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed BEAM chain at a 18-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 BEAM shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$35.00	$2.30
Buy 1	Put	$35.00	$2.48

BEAM straddle risk and reward

Net Premium / Debit: -$477.50
Max Profit (per contract): Unbounded
Max Loss (per contract): -$472.47
Breakeven(s): $30.23, $39.78
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit.

BEAM straddle payoff curve

Modeled P&L at expiration across a range of underlying prices for the straddle on BEAM. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

P&L at expiration across the modeled underlying-price range. Green shading marks profitable regions, red shading marks loss regions. Dotted purple verticals mark breakevens; the solid dark vertical marks current spot.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-100.0%	+$3,021.50
$7.70	-77.9%	+$2,252.83
$15.38	-55.8%	+$1,484.15
$23.07	-33.6%	+$715.48
$30.76	-11.5%	-$53.19
$38.44	+10.6%	-$133.13
$46.13	+32.7%	+$635.54
$53.82	+54.8%	+$1,404.21
$61.50	+76.9%	+$2,172.89
$69.19	+99.0%	+$2,941.56

When traders use straddle on BEAM

Straddles on BEAM are pure-volatility plays that profit from large moves in either direction; traders typically buy BEAM straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.

BEAM thesis for this straddle

The market-implied 1-standard-deviation range for BEAM extends from approximately $27.03 on the downside to $42.51 on the upside. A BEAM long straddle is a pure-volatility play: it profits when the underlying moves far enough from the strike in either direction to overcome the combined call plus put debit, regardless of direction. Current BEAM IV rank near 37.58% is mid-range against its 1-year distribution, so the IV signal is neutral; the straddle thesis on BEAM should anchor more to the directional view and the expected-move geometry. As a Healthcare name, BEAM options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to BEAM-specific events.

BEAM straddle positions are structurally neutral / high-volatility (long premium); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. BEAM positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move BEAM alongside the broader basket even when BEAM-specific fundamentals are unchanged. Always rebuild the position from current BEAM chain quotes before placing a trade.

Frequently asked questions

What is a straddle on BEAM?: A straddle on BEAM is the straddle strategy applied to BEAM (stock). The strategy is structurally neutral / high-volatility (long premium): A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration. With BEAM stock trading near $34.77, the strikes shown on this page are snapped to the nearest listed BEAM chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are BEAM straddle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the BEAM straddle priced from the end-of-day chain at a 30-day expiry (ATM IV 77.60%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$472.47 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a BEAM straddle?: The breakeven for the BEAM straddle priced on this page is roughly $30.23 and $39.78 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current BEAM market-implied 1-standard-deviation expected move is approximately 22.25%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a straddle on BEAM?: Straddles on BEAM are pure-volatility plays that profit from large moves in either direction; traders typically buy BEAM straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
How does current BEAM implied volatility affect this straddle?: BEAM ATM IV is at 77.60% with IV rank near 37.58%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.